# Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

> **NCT00304460** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 138 (actual)

## Conditions studied

- Metastatic Melanoma
- Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00304460
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-13
- **Primary completion:** 2014-02-27
- **Final completion:** 2014-02-27
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304460, "Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00304460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*